News
The stock's fall snapped a two-day winning streak.
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...
Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.
Then, a company named Regeneron announced they would buy the company, and would “prioritize [consumer data's] privacy, ...
Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...
The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...
Explore more
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...
If approved by the court, the 23andMe sale would put Anne Wojcicki back at the helm of the company she co-founded and previously attempted to take private.
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...
23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...
TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...
"It's cool to get the award, but what I submitted to it is so much more important to me," Cooper Taylor said about getting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results